Advertisement

Topics

Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones

09:12 EDT 24 Jul 2015 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Novartis International AG / Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this ...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...